rs17606561 — ELOVL2

ELOVL2 3'-UTR Variant — The DHA Bottleneck

Your body cannot make DHA from scratch. It relies on a metabolic relay: dietary alpha-linolenic acid (ALA) from plants is converted step by step — first to EPA, then elongated to DPA, and finally to DHA. The last two elongation steps in this relay are performed by ELOVL2, elongation of very long chain fatty acids protein 2¹¹ elongation of very long chain fatty acids protein 2
An endoplasmic reticulum enzyme that catalyses the rate-limiting elongation of EPA (20:5n-3) to DPA (22:5n-3) and then DPA to DHA (22:6n-3). DHA is the dominant structural fatty acid in the brain's grey matter and in photoreceptor cell membranes of the retina. The rs17606561 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The non-coding sequence at the end of an mRNA that controls message stability, translation efficiency, and miRNA binding — variants here can alter how much protein a gene produces without changing the protein's sequence of ELOVL2, where it may influence how efficiently the gene is expressed.

The Mechanism

Unlike missense variants that change ELOVL2's protein structure, this 3'UTR variant likely affects gene regulation — potentially altering ELOVL2 mRNA stability or its binding to microRNAs³³ microRNAs
Small non-coding RNA molecules that bind to mRNA 3'UTR sequences and suppress translation or promote degradation, fine-tuning protein output. The net effect is a shift in the EPA→DPA→DHA conversion step. Carriers of the A allele show a pattern consistent with partial ELOVL2 insufficiency⁴⁴ partial ELOVL2 insufficiency
Lower endogenous DHA synthesis capacity, reflected in reduced baseline DHA proportions in plasma phospholipids, with upstream EPA and DPA accumulating or being redirected: lower baseline circulating DHA despite normal EPA intake, with a compensatory up-regulation of the pathway in response to exogenous EPA/DHA — which is why minor allele carriers show a larger DHA response to fish oil supplementation.

The Evidence

The clearest evidence for ELOVL2 variants affecting omega-3 metabolism comes from the CHARGE Consortium meta-analysis⁵⁵ CHARGE Consortium meta-analysis
Lemaitre RN et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet, 2011, which examined 8,866 subjects of European ancestry across five cohorts. ELOVL2 minor alleles were robustly associated with higher plasma EPA (p=2×10⁻¹²), much higher DPA (p=1×10⁻⁴³), and significantly lower DHA (p=1×10⁻¹⁵) — a pattern that precisely matches a slowdown at the DPA→DHA elongation step: upstream metabolites accumulate while the downstream product (DHA) is reduced.

A direct supplementation study by Alsaleh and colleagues⁶⁶ Alsaleh and colleagues
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr, 2014 in 310 subjects found that ELOVL2 minor allele carriers had lower baseline plasma DHA but responded more strongly to fish oil supplementation: after 1.8 g/day EPA+DHA, minor allele carriers achieved approximately 30% higher EPA proportions and 9% higher DHA proportions than non-carriers. This paradox — lower baseline, larger response — is consistent with upregulation of an under-expressed enzyme when its substrate (EPA) is sharply increased.

The independent InCHIANTI/GOLDN genome-wide association study Tanaka et al.⁷⁷ Tanaka et al.
Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 also identified the ELOVL2 region as a significant locus for plasma n-3 fatty acid levels in 1,075 elderly Italian subjects, replicated in 1,076 subjects from the GOLDN study.

For rs17606561 specifically, a 2015 birth cohort study Barman et al.⁸⁸ Barman et al.
Barman M et al. Single Nucleotide Polymorphisms in the FADS Gene Cluster but not the ELOVL2 Gene are Associated with Serum Polyunsaturated Fatty Acid Composition and Development of Allergy. Nutrients, 2015 found nominally lower 20:4n-6 in cord serum among rs17606561 carriers, though the association did not survive multiple-testing correction in this smaller cohort (n=211). A Chinese case-control study Sun et al.⁹⁹ Sun et al.
Sun C et al. FADS1-FADS2 and ELOVL2 gene polymorphisms in susceptibility to autism spectrum disorders in Chinese children. BMC Psychiatry, 2018 found nominal association between rs17606561 A allele and autism spectrum disorder risk (OR=1.63, pFDR=0.036), consistent with the known importance of DHA for neurodevelopment, though this requires replication in larger cohorts.

Practical Actions

The key implication is that A allele carriers rely more heavily on preformed DHA from the diet because their endogenous synthesis is less efficient. Plant-based omega-3 sources (flaxseed, chia, walnuts) provide ALA, but the conversion to DHA requires a functional ELOVL2 step that is partially impaired in A allele carriers. Marine-sourced EPA and DHA — from fatty fish or algae-based supplements — bypass this bottleneck entirely.

For heterozygous AG individuals, moderate supplementation with preformed EPA/DHA is advisable. For homozygous AA individuals, the endogenous synthesis impairment is more pronounced; higher intakes of preformed DHA are particularly important, especially for pregnant women (for fetal brain development) and older adults (for retinal and cognitive maintenance).

Interactions

ELOVL2 works in concert with FADS1 and FADS2, which handle the earlier desaturation steps (ALA→SDA→EPA). Variants in FADS1 (rs174547) and FADS2 (rs174537) that reduce desaturase activity compound with ELOVL2 impairment: reduced input to the elongase (less EPA) combined with reduced elongase efficiency creates a double bottleneck for DHA synthesis. Individuals carrying risk alleles in both FADS and ELOVL2 genes have the strongest case for relying on preformed marine DHA rather than plant-based ALA precursors.